Injection lipolysis

Last updated

Injection lipolysis is a controversial cosmetic procedure in which drug mixtures are injected into patients with the goal of destroying fat cells. This practice, using drugs generally based on phosphatidylcholine and deoxycholate (PCDC), evolved from the initial intravenous use of those drug formulations to treat blood disorders. [1] [2]

Contents

While no placebo-controlled studies have demonstrated the safety or efficacy of this therapy, numerous retrospective studies of Lipostabil injections have reported the efficacy of this practice. [2] [3] [4] [5] [6] [7] [8] [9] [10] The mixture is injected directly into the subcutaneous fat through multiple microinjections administered over multiple treatment sessions. The desired result is the removal of localized fat deposits. [2]

History

In 1966, investigators noted that the intravenous infusion of PC-containing solutions could remove fat emboli. [11] Later, a drug formulation called Lipostabil containing 5% PC and 2.5% deoxycholate (DC) was approved in Germany and used in the treatment of fat embolism, [12] [13] dyslipidemia, [14] and alcohol-induced liver cirrhosis. [15] The first report of Lipostabil injection for fat removal demonstrated that infra-orbital ("under the eyelid") fat could be removed by Lipostabil injection. [16]

Kybella

In 2015, the US Food and Drug Administration approved deoxycholic acid (branded as Kybella) for use as an injection lipolysis product when used to reduce moderate to severe submental fullness (double chin). [17] [18] [19] While the procedure is generally considered safe when performed by a qualified healthcare professional, potential side effects may include swelling, bruising, numbness, and rarely, nerve injury in the treated area. [17] [18] [20]

Health warnings

Three medical associations have issued health warnings cautioning against the use of injection lypolysis, including the American Society of Plastic Surgeons (ASPS), the American Society for Aesthetic Plastic Surgery (ASAPS), and the American Society of Dermatologic Surgery (ASDS).The Aesthetic Surgery Education and Research Foundation has funded on behalf of the American Society for Aesthetic Plastic Surgery a half side comparison study with interesting results [21]

Restrictive action taken by FDA against Lipodissolve

On April 7, 2010, the US Food and Drug Administration issued Warning Letters to six U.S. based medspas and a company in Brazil for making false or misleading statements on their Web sites about drugs they claimed will eliminate fat in a procedure called "lipodissolve", or for otherwise misbranding lipodissolve products. "We are concerned that these companies are misleading consumers", said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "It is important for anyone who is considering this voluntary procedure to understand that the products used to perform lipodissolve procedures are not approved by the FDA for fat removal".

For the complete FDA statement, see here . To see the warning letter, see .

The FDA received reports of adverse effects in persons who had the procedure using these drugs, including permanent scarring, skin deformation, and deep painful knots under the skin in areas where the lipodissolve products have been injected. The warning letters were issued to the following U.S. companies: Monarch Medspa, King of Prussia, Pa; Spa 35, Boise, Idaho; Medical Cosmetic Enhancements, Chevy Chase, Md.; Innovative Directions in Health, Edina, Minn PURE Med Spa, Boca Raton, Fl.; and All About You Med Spa, Madison, Ind. The Brazilian company receiving a warning letter markets lipodissolve products on two Web sites: zipmed.net and mesoone.com.

The FDA is requesting a written response from the U.S. companies within 15 business days of receipt of the warning letters stating how they will correct these violations and prevent similar violations in the future. Each U.S. company has been informed in its warning letter that failure to promptly correct the violations may result in legal action. Each of the companies involved has been cited for a variety of regulatory violations, including making unsupported claims that the products have an outstanding safety record and are superior to other fat loss procedures, including liposuction. Additionally some of the letters indicate that the companies have made claim that lipodissolve products can be used to treat certain medical conditions, such as male breast enlargement, benign fatty growths known as lipomas, excess fat deposits and surgical deformities. The FDA is not aware of clinical evidence to support any of these claims.[ citation needed ]

International regulation

The Medicines and Healthcare products Regulatory Agency, the governmental body regulating the manufacture and commercialization of drugs in the United Kingdom, issued a similar warning to physicians considering the use of these substances for cosmetic purposes, stating these drugs "are being unlawfully advertised in the UK as a cosmetic product for the reduction of fat." The MHRA also pointed out that considerable safety concerns remain because these agents have not been tested in controlled clinical trials. While British physicians can still inject Lipodissolve for fat removal, the drug cannot be promoted as a drug for that purpose. As of July, 2005, The Medical Protection Society, the organization that provides British doctors with legal advice and coverage against litigation costs and damages, ceased offering malpractice insurance for use of Lipodissolve because of safety concerns. [22]
On the other hand, the therapy is very often administered especially in German speaking countries because the drug Lipostabil N has been approved in Germany for more than 40 years. A physicians' network, the NETWORK-Lipolysis with 3,000 members worldwide amongst them 1,000 alone in German speaking countries has collected safety data. The latest published so-called Lipolysis Report 2015 has been published in 2016. [23] 4% of the members have answered the survey. 29,889 patient results have been collected with in total ca. 76,000 treatment sessions. Nowadays the composition is compounded by pharmacies in Germany and Switzerland.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Botulinum toxin</span> Neurotoxic protein produced by Clostridium botulinum

Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.

<span class="mw-page-title-main">Scar</span> Area of fibrous tissue that replaces normal skin after an injury

A scar is an area of fibrous tissue that replaces normal skin after an injury. Scars result from the biological process of wound repair in the skin, as well as in other organs, and tissues of the body. Thus, scarring is a natural part of the healing process. With the exception of very minor lesions, every wound results in some degree of scarring. An exception to this are animals with complete regeneration, which regrow tissue without scar formation.

<span class="mw-page-title-main">Penis enlargement</span> Technique aimed to increase the size of a human penis

Penis enlargement, or male enhancement, is any technique aimed to increase the size of a human penis. Some methods aim to increase total length, others the shaft's girth, and yet others the glans size. Techniques include surgery, supplements, ointments, patches, and physical methods like pumping, jelqing, and traction.

<span class="mw-page-title-main">Lipoma</span> Benign tumor made of fat tissue

A lipoma is a benign tumor made of fat tissue. They are generally soft to the touch, movable, and painless. They usually occur just under the skin, but occasionally may be deeper. Most are less than 5 cm (2.0 in) in size. Common locations include upper back, shoulders, and abdomen. It is possible to have several lipomas.

<span class="mw-page-title-main">Phosphatidylcholine</span> Class of phospholipids

Phosphatidylcholines (PC) are a class of phospholipids that incorporate choline as a headgroup. They are a major component of biological membranes and can be easily obtained from a variety of readily available sources, such as egg yolk or soybeans, from which they are mechanically or chemically extracted using hexane. They are also a member of the lecithin group of yellow-brownish fatty substances occurring in animal and plant tissues. Dipalmitoylphosphatidylcholine (lecithin) is a major component of the pulmonary surfactant, and is often used in the lecithin–sphingomyelin ratio to calculate fetal lung maturity. While phosphatidylcholines are found in all plant and animal cells, they are absent in the membranes of most bacteria, including Escherichia coli. Purified phosphatidylcholine is produced commercially.

Mesotherapy is a form of alternative medicine which involves intradermal or subcutaneous injections of pharmaceutical preparations, enzymes, hormones, plant extracts, vitamins, and/or other ingredients such as hyaluronic acid. It has no proven clinical efficacy and poor scientific backing. Mesotherapy injections allegedly target adipose fat cells, apparently by inducing lipolysis, rupture and cell death among adipocytes. The stated aim of mesotherapy is to provide the skin with essential nutrients, hydration, and other beneficial compounds to rejuvenate and revitalize its appearance.

<span class="mw-page-title-main">Hyperhidrosis</span> Excessive sweating

Hyperhidrosis is a medical condition in which a person exhibits excessive sweating, more than that required for the regulation of body temperature. Although it is primarily a physical burden, hyperhidrosis can deteriorate the quality of life of the people who are affected from a psychological, emotional, and social perspective. In fact, hyperhidrosis almost always leads to psychological as well as physical and social consequences. People suffering from it present difficulties in professional fields, more than 80% experiencing a moderate to severe emotional impact from the disease and half are subject to depression.

<span class="mw-page-title-main">Deoxycholic acid</span> Bile acid

Deoxycholic acid is a bile acid. Deoxycholic acid is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria. The two primary bile acids secreted by the liver are cholic acid and chenodeoxycholic acid. Bacteria metabolize chenodeoxycholic acid into the secondary bile acid lithocholic acid, and they metabolize cholic acid into deoxycholic acid. There are additional secondary bile acids, such as ursodeoxycholic acid. Deoxycholic acid is soluble in alcohol and acetic acid. When pure, it exists in a white to off-white crystalline powder form.

Restylane is the trade name for a range of injectable fillers with a specific formulation of non-animal sourced hyaluronic acid (HA).

Artefill is a permanent injectable wrinkle filler, for the correction of smile lines. Artefill was approved by the U.S. Food and Drug Administration (FDA) as a medical device in October 2006. A prior version of the product called Artecoll has been marketed in Canada and Europe since the 1990s.

Carboxytherapy is a non-surgical cosmetic medicine treatment for dermatology. Carboxytherapy employs injections or transdermal application to infuse gaseous carbon dioxide below the skin into the subcutaneous tissue through a needle or skin. It has a necrotizing effect on fat tissue fat cells, stimulates blood flow, improves the skin's elasticity and reduces the appearance of cellulite. It has also become a popular treatment for stretch marks. It is non-toxic and less invasive than operations like liposuction. Carboxytherapy leads to a temporary decrease in subcutaneous fat but has shown to reoccur again after a 28 week period. It can be applied for those with androgenic alopecia or alopecia areata.

<span class="mw-page-title-main">Liposuction</span> Surgery to remove unwanted fat

Liposuction, or simply lipo, is a type of fat-removal procedure used in plastic surgery. Evidence does not support an effect on weight beyond a couple of months and does not appear to affect obesity-related problems. In the United States, liposuction is the most common cosmetic surgery.

<span class="mw-page-title-main">Benign symmetric lipomatosis</span> Medical condition

Benign symmetric lipomatosis, also known as Madelung's disease, is an adult-onset skin condition characterized by extensive symmetric fat deposits in the head, neck, and shoulder girdle area. The symmetrical fat deposits are made of unencapsulated lipomas, which distinguishes it from typical lipomatosis which has encapsulated lipomas that are not usually symmetrical. Benjamin Brodie described the condition in 1846. The German surgeon Otto Wilhelm Madelung was the first to give a detailed description of the disorder in 1888, followed by Launois and Bensaude in 1898.

<span class="mw-page-title-main">Pulsed electromagnetic field therapy</span> Attempted medical therapy using electromagnetic fields

Pulsed electromagnetic field therapy, also known as low field magnetic stimulation (LFMS) is the use of electromagnetic fields in an attempt to heal non-union fractures and depression. By 2007 the FDA had cleared several such stimulation devices.

Aesthetic medicine is a branch of modern medicine that focuses on altering natural or acquired unwanted appearance through the treatment of conditions including scars, skin laxity, wrinkles, moles, liver spots, excess fat, cellulite, unwanted hair, skin discoloration, spider veins and or any unwanted externally visible appearance. Traditionally, it includes dermatology, oral and maxillofacial surgery, reconstructive surgery and plastic surgery, surgical procedures, non-surgical procedures, and a combination of both. Aesthetic medicine procedures are usually elective. There is a long history of aesthetic medicine procedures, dating back to many notable cases in the 19th century, though techniques have developed much since then.

<span class="mw-page-title-main">Cellulite</span> Medical condition

Cellulite or gynoid lipodystrophy (GLD) is the herniation of subcutaneous fat within fibrous connective tissue that manifests as skin dimpling and nodularity, often on the pelvic region, lower limbs, and abdomen. Cellulite occurs in most postpubescent females. A review gives a prevalence of 85–98% of women of European descent, but it is considerably less common in women of East Asian descent. It is believed to be physiological rather than pathological. It can result from a complex combination of factors, including diet, sedentary lifestyle, hormonal imbalance or heredity, among others.

<span class="mw-page-title-main">Mitchel P. Goldman</span> American dermatologic surgeon (born 1955)

Mitchel P. Goldman, is an American dermatologic surgeon, cosmetic surgeon, dermatologist, and phlebologist, and the founder and director of Cosmetic Laser Dermatology. He is also a past president of the American Society for Dermatologic Surgery, the American College of Phlebology, the San Diego County Dermatology Society, and the Sonoran Dermatology Society.

Injectable filler is a soft tissue filler made of polysaccharides injected into the skin at different depths.

Fat removal procedures are used mostly in cosmetic surgery with the intention of removing unwanted adipose tissue. The procedure may be invasive, as with liposuction, or noninvasive using laser therapy, radiofrequency, ultrasound or cold to reduce fat, sometimes in combination with injections.

Tina S. Alster, MD, FAAD, is an American dermatologist, educator, researcher, and author. Alster specializes in dermatologic laser surgery and cosmetic dermatology. She is the founding director of her skin care clinic, the Washington Institute of Dermatologic Laser Surgery, and is a Clinical Professor of Dermatology at Georgetown University Medical Center in Washington, D.C.

References

  1. ↑ Matarasso, A.; Pfeifer, T.M. (2005). "Mesotherapy for body contouring". Plast Reconstr Surg. 115 (Pt 5): 1420–4. doi:10.1097/01.PRS.0000162227.94032.ED. PMID   15809611. S2CID   38159936.
  2. 1 2 3 Duncan, D.I.; Hasengschwandtner, F (2005). "Lipodissolve for Subcutaneous Fat Reduction and Skin Retraction". Aesthet Surg J. 25 (Pt 5): 530–543. doi: 10.1016/j.asj.2005.07.009 . PMID   19338857.
  3. ↑ Rotunda, A.M., M.M. Avram, and Avram, A.S. (2005). "Cellulite: Is there a role for injectables?". Journal of Cosmetic and Laser Therapy. 7 (3–4): 147–54. doi:10.1080/14764170500430234. PMID   16414902. S2CID   40625377.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ Ablon G, Rotunda, AM. (2004). "Treatment of lower eyelid fat pads using phosphatidylcholine: clinical trial and review". Dermatologic Surgery. 30 (3): 422–7. doi:10.1097/00042728-200403000-00020. PMID   15008874.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ↑ Hexsel, D., Serra, M., Mazzuco, R. (2003). "Phosphatidylcholine in the treatment of localized fat". Journal of Drugs in Dermatology. 2 (5): 511–8. PMID   14558399.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ↑ Rotunda, A.M., G. Ablon, and M.S. Kolodney (2005). "Lipomas treated with subcutaneous deoxycholate injections". Journal of the American Academy of Dermatology. 53 (6): 973–8. doi:10.1016/j.jaad.2005.07.068. PMID   16310057.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ↑ Rotunda, A.M.; M.S. Kolodney (2006). "Mesotherapy and Phosphatidylcholine Injections: Historical Clarification and Review". Dermatologic Surgery. 32 (4): 465–480. CiteSeerX   10.1.1.506.2372 . doi:10.1111/j.1524-4725.2006.32100.x. PMID   16681654. S2CID   9994696.
  8. ↑ Bechara, F.G., Sand, M., Hoffmann, K., Sand, D., Altmeyer, P., and Stucker, M. (2007). "Fat tissue after lipolysis of lipomas: a histopathological and immunohistochemical study". Journal of Cutaneous Pathology. 34 (7): 552–7. doi:10.1111/j.1600-0560.2006.00651.x. PMID   17576334. S2CID   39429064.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ↑ Bechara, F.G., Sand, M., Altmeyer, P., and Hoffmann, K. (2006). "Intralesional lipolysis with phosphatidylcholine for the treatment of lipomas: pilot study". Arch Dermatol. 142 (8): 1069–70. doi:10.1001/archderm.142.8.1069-b. PMID   16924064.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ Bechara, F.G., Sand, M., Sand, D., Rotterdam, S., Stucker, M., Altmeyer, P., and Hoffmann, K. (2006). "Lipolysis of lipomas in patients with familial multiple lipomatosis: an ultrasonography-controlled trial". Journal of Cutaneous Medicine and Surgery . 10 (4): 155–9. doi:10.2310/7750.2006.00040. PMID   17234112. S2CID   45970041.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ↑ Kroupa, J. (1966). "Lipostabil in the prevention of fat embolism. (Experimental study)". Rozhl Chir. 45 (Pt 7): 444–452. PMID   5924189.
  12. ↑ Schroder, D., Buttenschon, K., Herrmann, F., Brede, S. (1991). "Is there a drug treatment approach for prevention and therapy of fat embolism syndrome?". Klin Wochenschr. 69 (Pt 26): 229–233.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ↑ Stohlmacher, P., Haferland, W., and Gottschall, S. (1975). "Diffuse foam cell pneumonia following fatty embolism treated with lipostabil. A contribution to the pathology of therapy". Z Arztl Fortbild (Jena). 69 (5): 237–239. PMID   1226856.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Klimov, A.N., Konstantinov, V.O., Lipovetsky, B.M., Kuznetsov, A.S., Lozovsky, V.T., Trufanov, V.F., Plavinsky, S.L., Gundermann, K.J., and Schumacher. R.. (1995). ""Essential" phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease". Cardiovascular Drugs and Therapy. 9 (6): 779–784. doi:10.1007/bf00879871. PMID   8850382. S2CID   21578474.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ↑ Lieber, C.S., Weiss, D.G., Groszmann, R., Paronetto, F., Schenker, S. (2003). "For the Veterans Affairs Cooperative Study 391 Group., II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease". Alcohol Clin Exp Res. 27 (11): 1765–1772. doi:10.1097/01.alc.0000093743.03049.80. PMID   14634492.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ↑ Rittes, P.G. (2001). "The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads". Dermatologic Surgery. 27 (4): 391–2. doi:10.1097/00042728-200104000-00014. PMID   11298713.
  17. 1 2 Liu M, Chesnut C, Lask G (June 2019). "Overview of Kybella (Deoxycholic Acid Injection) as a Fat Resorption Product for Submental Fat". Facial Plastic Surgery. 35 (3): 274–277. doi:10.1055/s-0039-1688943. PMID   31189201.
  18. 1 2 Farina GA, Cherubini K, de Figueiredo MA, Salum FG (October 2020). "Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications". Journal of Cosmetic Dermatology. 19 (10): 2497–2504. doi:10.1111/jocd.13619. hdl: 10923/18644 . PMID   32654409.
  19. ↑ "FDA approves treatment for fat below the chin". Food and Drug Administration. April 29, 2015. Archived from the original on May 1, 2015. Retrieved December 16, 2019.
  20. ↑ Murdock, Joshua (3 May 2022). "The 10 Kybella Side Effects: What to Expect". GoodRx. Retrieved 1 June 2024.
  21. ↑ Dominic N. Reeds, B. Selma Mohammed, Samuel Klein, Craig Brian Boswell and V. Leroy Young (2013), "Metabolic and Structural Effects of Phosphatidylcholine and Deoxycholate Injections on Subcutaneous Fat: A Randomized, Controlled Trial", Aesthetic Surgery Journal., vol. 33, no. 3, pp. 400–408, doi:10.1177/1090820X13478630, PMC   3667691 , PMID   23439063 {{citation}}: CS1 maint: multiple names: authors list (link)
  22. ↑ Lister, Sam (July 18, 2005). "Youre on your own if you give flab jab insurers warn doctors". The Times. London. Retrieved May 5, 2010.[ dead link ]
  23. ↑ Weidmann M, Lettko M, Prantl L (2016), "Injektionslipolyse", J Ästhet Chir. (in German), vol. 9, no. 4, pp. 158–167, doi:10.1007/s12631-016-0047-2 {{citation}}: CS1 maint: multiple names: authors list (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.